睿知中国医院研究地图
候选清单

即将招募淋巴瘤II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由上海交通大学医学院附属瑞金医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方上海交通大学医学院附属瑞金医院Ruijin Hospital上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07613788,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Histologically confirmed large B-cell lymphoma with CD19 and CD20 expression.

    入选标准第 3 条

  3. Prior treatment must have included an anthracycline-containing chemotherapy regimen and an anti-CD20 monoclonal antibody.

    入选标准第 5 条

  4. ECOG performance status of 0 to 2.

    入选标准第 8 条

  5. History of another malignancy within 5 years before screening, except adequately treated carcinoma in situ or non-melanoma skin cancer.

    排除标准第 10 条

  6. Pregnant or breastfeeding women, or participants planning pregnancy during the study period.

    排除标准第 12 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07613788,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Able to understand and voluntarily sign the written informed consent form.
  2. Age 18 years or older.
  3. Histologically confirmed large B-cell lymphoma with CD19 and CD20 expression.
  4. Relapsed or refractory disease after at least one prior line of systemic therapy.
  5. Prior treatment must have included an anthracycline-containing chemotherapy regimen and an anti-CD20 monoclonal antibody.
  6. Considered suitable by the investigator to receive glofitamab and CD19 CAR-T cell therapy.
  7. Presence of at least one high-risk feature, including extranodal involvement, bulky disease, or TP53 abnormality.
  8. ECOG performance status of 0 to 2.
  9. Life expectancy of at least 12 weeks.
  10. Adequate bone marrow, hepatic, renal, pulmonary, and cardiac function as determined by the investigator.
  11. Participants of reproductive potential must agree to use effective contraception during the study period.
  12. Able and willing to comply with the study protocol, in the investigator's judgment.

排除标准:Exclusion Criteria:

  1. History of hypersensitivity to any study treatment or related compounds.
  2. Active or uncontrolled infection requiring systemic treatment.
  3. History of allogeneic hematopoietic stem cell transplantation or organ transplantation.
  4. Uncontrolled or clinically significant viral infection as defined by the protocol.
  5. Known central nervous system involvement by lymphoma or clinically significant central nervous system disease that may interfere with study treatment or safety assessment.
  6. Severe or uncontrolled cardiovascular disease.
  7. Severe autoimmune disease or immune-mediated disease that may interfere with study treatment or safety assessment.
  8. Known or suspected history of hemophagocytic lymphohistiocytosis.
  9. Recent thromboembolic event before screening.
  10. History of another malignancy within 5 years before screening, except adequately treated carcinoma in situ or non-melanoma skin cancer.
  11. Receipt of prohibited anticancer therapy, immunosuppressive therapy, live attenuated vaccine, or other prohibited treatment within the protocol-specified period before enrollment.
  12. Pregnant or breastfeeding women, or participants planning pregnancy during the study period.
  13. Concurrent participation in another interventional clinical trial.
  14. Need for prohibited concomitant medications that cannot be discontinued or substituted.
  15. Any condition that, in the investigator's judgment, makes the participant unsuitable for study treatment or study participation.

引自 ClinicalTrials.gov, NCT07613788, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07613788,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07613788